NCT07171606

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC

Detailed description

This study is a study of SSGJ-706 monotherapy and combination therapy for advanced NSCLC Patients. This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC. Each part will assess the efficacy and safety of the preset several dose levels of SSGJ-706 in advanced NSCLC Patients.

Conditions

• First-line Advanced NSCLC Patients

Interventions

Type	Name	Description
DRUG	SSGJ-706	PD-1/PD-L1 bispecific antibody
DRUG	pemetrexed /carboplatin	chemotherapy
DRUG	Carboplatin/Paclitaxel	chemotherapy
DRUG	PD-1 Inhibitor + Chemotherapy	control group

Timeline

• Start date: 2025-10-24
• Primary completion: 2026-08-31
• Completion: 2027-08-31
• First posted: 2025-09-12
• Last updated: 2025-12-18

Locations

1 site across 1 country: China